Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures.

Published

Journal Article

Antifungal expenditures are substantial for many hospitals. Using caspofungin for the treatment of candidemia accounts for a sizable proportion of the costs. A cost minimization study that used a decision analytic model was done to compare in-hospital diagnosis and treatment costs using the Candida albicans peptide nucleic acid fluorescence in situ hybridization (PNA FISH) test versus the C. albicans screen test for differentiating C. albicans from non-albicans Candida species bloodstream infections. Assuming physician notification of yeast identity concurrent with blood culture positivity, potential savings resulting from use of the C. albicans PNA FISH test compared with the C. albicans screen test averaged $1837 per patient treated, although laboratory costs for doing the C. albicans PNA FISH test ($82.72) exceeded those for the C. albicans screen test ($2.83). Savings were realized through a decrease in antifungal drug costs, particularly caspofungin. Incorporating the C. albicans PNA FISH test as part of the initial identification algorithm for yeasts recovered from blood can result in substantial savings for hospitals.

Full Text

Duke Authors

Cited Authors

  • Alexander, BD; Ashley, ED; Reller, LB; Reed, SD

Published Date

  • April 2006

Published In

Volume / Issue

  • 54 / 4

Start / End Page

  • 277 - 282

PubMed ID

  • 16466898

Pubmed Central ID

  • 16466898

International Standard Serial Number (ISSN)

  • 0732-8893

Digital Object Identifier (DOI)

  • 10.1016/j.diagmicrobio.2005.10.011

Language

  • eng

Conference Location

  • United States